PHEN Clinical Trials Rally

Increasing the participation of African American men in prostate cancer clinical trials through education, awareness, support and collaborations. This portal provides clinical trials background information, details for specific trials, personal stories and other resources to support the Rally.

This information is not intended as medical advice for patients. Patients should consult their medical doctor for advice and recommendations about specific clinical trials.


"We must not be left behind with new prostate cancer treatments."

PHEN president and founder Thomas A. Farrington talks about his prostate cancer journey and the importance of African American men participating in clinical trials.

Information

Understanding the possible benefits for patients when participating in a clinical trial.

Clinical trials offer important and unique benefits to patients.

Information

Dr. J. Carter Presents Clinical Trials 101

Dr. Carter's brief video presentations provide basic information for patients to better understand clinical trials.

Information

What Are Clinical Trials?

Information that all patients need to know when considering enrolling into a clinical trial.

Information

CA209-9KD

This is a clinical research study for men with metastatic prostate cancer (cancer that has spread) that no longer responds to androgen deprivation therapy treatments that lower testosterone.

Information

IPATential150 Clinical Trial

This trial is for patients with metastatic castration-resistant Prostate Cancer who are eligible for, but have not yet begun, abiraterone (Zytiga) treatment.

Information

ARASENS Clinical Trials Summary

For men who have metastatic cancer and who have never been treated with chemotherapy or immunotherapy.

Information

Triton 2 Clinical Trial

For patients with metastatic castration resistant prostate cancer that is progressing following treatment with Zytiga, Xtandi, and taxane based chemotherapy

Information

Triton 3 Clinical Trial

For patients where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of BRCA1, BRCA2, or ATM genetic mutations or alterations

Information

ENACT Clinical Trial Summary

For patients considering active surveillance or currently undergoing active surveillance.

Information

EMBARK Clinical Trial Summary

For patients with a rising PSA after being treated with surgery, radiation or both.

Information

The TRUMPET Registry

For men whose prostate cancer has grown or spread despite use of hormonal treatments to lower their PSA; Known as castration-resistant prostate cancer.

Information

Low and Intermediate Risk Prostate Cancer



Information
Newly Diagnosed High Risk


Newly Diagnosed High Risk


Information
Treated with Prostatectomy  /Radiation


Treated with Prostatectomy /Radiation


Information
Recurrent Disease


Recurrent Disease


Information
Castration Resistant non-Metastatic


Castration Resistant non-Metastatic


Information
Metastatic Castration Resistant


Metastatic Castration Resistant


Information

Actively Recruiting Trials by Class of Drug

A description of the classes of drugs being studied for prostate cancer treatment with a selective listing of actively recruiting trials by class.

Information



A listing of all the prostate cancer clinical trials listed on clinicaltrials.gov that are currently recruiting patients.

Information

Strategies For Increasing African American Participation in Clinical Trials at Duke

Dr. Steven Patierno, Deputy Director, Duke Cancer Institute at Duke Medical Center presents at PHEN's 2016 Summit.

Information

Overcoming Barriers to Clinical Trials Participation

Dr. Edith Mitchell, Director, Center to Eliminate Cancer Disparities, Sidney Kimmel Cancer Center at Thomas Jefferson University presents at PHEN's 2016 Summit.

Information






















PHEN,Inc. © 2018 All rights reserved